Viking Therapeutics, Inc.
VKTX
$31.32
-$0.40-1.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -0.42% | -73.66% | -38.48% | -43.68% | -28.83% |
| Total Depreciation and Amortization | -9.57% | -17.54% | 1.79% | 0.90% | 0.91% |
| Total Amortization of Deferred Charges | -- | -100.00% | -66.67% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 33.03% | 28.16% | -52.46% | 35.68% | 399.70% |
| Change in Net Operating Assets | -46.21% | 857.60% | -219.98% | 147.83% | -713.27% |
| Cash from Operations | -33.63% | 9.27% | -99.75% | 10.07% | -67.83% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -28.33% | -52.75% | 276.48% | -32.79% | 860.59% |
| Cash from Investing | -28.33% | -52.75% | 276.48% | -32.79% | 860.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -83.92% | 15,546.46% | -5.33% | 45.27% | -65.10% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -83.92% | 15,546.46% | -5.33% | 45.27% | -65.10% |
| Foreign Exchange rate Adjustments | 77.78% | 250.00% | 50.00% | -1,300.00% | 101.35% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -172.89% | -1.60% | 1,737.83% | -136.04% | 147.59% |